Profile data is unavailable for this security.
About the company
Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.
- Revenue in USD (TTM)0.00
- Net income in USD-24.99m
- Incorporated2016
- Employees31.00
- LocationKiromic Biopharma Inc7707 Fannin St., Suite 140HOUSTON 77054United StatesUSA
- Phone+1 (832) 968-4888
- Fax+1 (302) 655-5049
- Websitehttps://kiromic.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc | 449.00k | -19.85m | 3.86m | 12.00 | -- | -- | -- | 8.60 | -21.99 | -21.99 | 0.4636 | -1.67 | 0.0318 | -- | 0.1204 | -- | -139.57 | -57.58 | -314.22 | -69.81 | -- | -- | -4,386.86 | -18,789.29 | -- | -128.51 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 3.96m | 24.00 | -- | -- | -- | 0.2784 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| Phio Pharmaceuticals Corp | 0.00 | -9.38m | 3.98m | 8.00 | -- | 0.5981 | -- | -- | -3.71 | -3.71 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -113.26 | -71.92 | -145.23 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Alzamend Neuro Inc | 0.00 | -12.40m | 4.06m | 4.00 | -- | -- | -- | -- | -1.87 | -1.87 | 0.00 | -0.572 | 0.00 | -- | -- | 0.00 | -267.15 | -- | -880.90 | -- | -- | -- | -- | -- | -- | -1,352.90 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
| Evoke Pharma Inc | 6.11m | -7.13m | 4.08m | 4.00 | -- | 1.17 | -- | 0.6688 | -1.83 | -1.83 | 1.28 | 0.4068 | 0.5429 | 0.5113 | 5.71 | 1,526,428.00 | -63.39 | -100.48 | -76.67 | -151.10 | 96.01 | -- | -116.76 | -480.52 | 5.35 | -19.25 | 0.5884 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Regen BioPharma Inc | 236.58k | -851.69k | 4.11m | 1.00 | -- | -- | -- | 17.39 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -24.99m | 4.12m | 31.00 | -- | -- | -- | -- | -29.21 | -29.21 | 0.00 | -3.81 | 0.00 | -- | -- | 0.00 | -171.18 | -161.49 | -- | -213.01 | -- | -- | -- | -- | -- | -15.69 | 1.87 | -- | -- | -- | -35.90 | -- | 177.42 | -- |
| Zyversa Therapeutics Inc | 0.00 | -105.53m | 4.12m | 7.00 | -- | 0.3675 | -- | -- | -1,791.54 | -1,791.54 | 0.00 | 13.44 | 0.00 | -- | -- | 0.00 | -142.87 | -- | -164.77 | -- | -- | -- | -- | -- | -- | -17,576.86 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Neximmune Inc | 0.00 | -25.86m | 4.20m | 6.00 | -- | 1.53 | -- | -- | -24.16 | -24.16 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -130.41 | -115.07 | -183.16 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| Processa Pharmaceuticals Inc | 0.00 | -9.83m | 4.23m | 13.00 | -- | 0.4758 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 4.29m | 9.00 | -- | 0.1897 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Petros Pharmaceuticals Inc | 4.69m | -20.46m | 4.30m | 21.00 | -- | 0.4319 | -- | 0.9161 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -19.04m | 4.32m | 21.00 | -- | 0.1366 | -- | -- | -1.15 | -1.15 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -32.65 | -36.95 | -37.33 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Ensysce Biosciences Inc | 1.75m | -11.55m | 4.36m | 7.00 | -- | 1.12 | -- | 2.50 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Cingulate Inc | 0.00 | -22.50m | 4.37m | 13.00 | -- | 1.09 | -- | -- | -22.66 | -22.66 | 0.00 | 0.6419 | 0.00 | -- | -- | 0.00 | -355.56 | -- | -1,198.96 | -- | -- | -- | -- | -- | -- | -33.88 | 0.0054 | -- | -- | -- | -33.14 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Yorkville Advisors Global LPas of 15 May 2024 | 171.19k | 13.29% |
| Sabby Management LLCas of 31 Dec 2023 | 0.00 | 0.00% |
